Terhune Julia, Berk Erik, Czerniecki Brian J
Department of Surgery and Harrison Department of Surgical Research, University of Pennsylvania, Philadelphia, PA 19104, USA.
Rena Rowan Breast Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Vaccines (Basel). 2013 Nov 21;1(4):527-49. doi: 10.3390/vaccines1040527.
The success of cellular immunotherapies against cancer requires the generation of activated CD4⁺ and CD8⁺ T-cells. The type of T-cell response generated (e.g., Th1 or Th2) will determine the efficacy of the therapy, and it is generally assumed that a type-1 response is needed for optimal cancer treatment. IL-17 producing T-cells (Th17/Tc17) play an important role in autoimmune diseases, but their function in cancer is more controversial. While some studies have shown a pro-cancerous role for IL-17, other studies have shown an anti-tumor function. The induction of polarized T-cell responses can be regulated by dendritic cells (DCs). DCs are key regulators of the immune system with the ability to affect both innate and adaptive immune responses. These properties have led many researchers to study the use of ex vivo manipulated DCs for the treatment of various diseases, such as cancer and autoimmune diseases. While Th1/Tc1 cells are traditionally used for their potent anti-tumor responses, mounting evidence suggests Th17/Tc17 cells should be utilized by themselves or for the induction of optimal Th1 responses. It is therefore important to understand the factors involved in the induction of both type-1 and type-17 T-cell responses by DCs.
细胞免疫疗法对抗癌症的成功需要产生活化的CD4⁺和CD8⁺ T细胞。所产生的T细胞反应类型（例如，Th1或Th2）将决定治疗的疗效，并且通常认为最佳癌症治疗需要1型反应。产生白细胞介素-17的T细胞（Th17/Tc17）在自身免疫性疾病中起重要作用，但其在癌症中的功能更具争议性。虽然一些研究表明白细胞介素-17具有促癌作用，但其他研究表明其具有抗肿瘤功能。极化T细胞反应的诱导可由树突状细胞（DC）调节。DC是免疫系统的关键调节因子，能够影响先天和适应性免疫反应。这些特性促使许多研究人员研究使用体外操纵的DC来治疗各种疾病，如癌症和自身免疫性疾病。虽然传统上使用Th1/Tc1细胞是因其强大的抗肿瘤反应，但越来越多的证据表明Th17/Tc17细胞应单独使用或用于诱导最佳的Th1反应。因此，了解DC诱导1型和17型T细胞反应所涉及的因素很重要。
